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Breast cancer is the most common malignancy among
women, leading to approximately 45 000 deaths per annum in
the United States (1). The presence of axillary lymph node me-
tastases has major prognostic implications in breast cancer pa-
tients (2,3), and it is an important criterion in determining the
need for adjuvant chemotherapy (4). Sentinel lymph node (SLN)
biopsy has become routine practice in the surgical treatment of
patients with breast cancer because the disease status of the
SLNs accurately reflects the status of the remaining axillary
lymph nodes (5–7). Hence, patients who present with a negative
SLN (no metastases) can be spared from having a more trau-
matic axillary lymph node dissection (ALND), which has been
shown to be associated with substantial short- and long-term
sequelae (8,9). Despite the enormous advantages of SLN biopsy
over ALND in regard to post-operative complications in node-
negative patients, it would be of great clinical benefit if a reliable
non-invasive method to assess lymph node status in breast can-
cer patients could be found.
Positron emission tomography (PET) reflects the biochemical
and physiologic processes occurring in the tissues being imaged
and has been used in diagnosing a variety of malignancies (10,
11). The most frequently used positron emitting radiopharma-
ceutical is 18-fluor labeled 2-deoxy-D-glucose (18F-FDG), a ra-
dioactively labeled glucose analog. The clinical use of 18F-FDG–PET
is based on the premise that cancer cells exhibit a higher glyco-
lytic rate than do non-neoplastic cells. Thus, 18F-FDG accumu-
lates predominantly in the tumor tissue and can be visualized by
a PET camera. Since the first reported visualization of lymph
node metastases with 18F-FDG–PET in a preclinical animal
study in 1990 (12), several investigations (13–19) have assessed
the accuracy of PET in evaluating the nodal status of patients
with breast cancer. These investigations have yielded conflicting
results, with some investigators doubting that 18F-FDG–PET is
capable of accurately assessing the nodal status of breast cancer
patients (13–16) and others believing that a noninvasive PET
scan could replace SLN biopsy at predicting the disease status of
the axillary lymph nodes (17–19).
In a recent investigation by an Italian group (18), pre-
operative 18F-FDG–PET was compared with the histologic find-
ings of ALND in 167 clinically node-negative T1 (tumor size
2cm) and T2 (tumor size >2cm to 5cm) breast cancer pa-
tients, the largest patient collective published. 18F-FDG–PET
detected 68 of 72 patients with axillary metastases, resulting in
an overall sensitivity for PET of 94%. In the subset of T2 pa-
tients, the sensitivity was even higher (98%; 48/49), with only
one false-negative finding. Based on these results, the authors
claimed that 18F-FDG–PET can safely predict axillary lymph
node status in patients with breast cancer and is a reliable and
accurate method to identify patients who can avoid ALND. In
the second largest published patient collective (19), pre-
operative 18F-FDG–PET was compared with the histologic find-
ings of ALND in 124 pT1–T3 (T3 tumor size >5cm) breast
cancer patients. PET scanning correctly identified all 44 patients
with axillary lymph node metastases, resulting in an overall
sensitivity for PET of 100%. These findings led the investigators
of that study to suggest that 18F-FDG–PET should be considered
as the initial test in evaluating axillary lymph nodes in breast
cancer patients and that those patients without increased axillary
18F-FDG-uptake may not require ALND. Other investigations
(17,20–23) with smaller patient numbers have reported similar
findings, with sensitivities of pre-operative 18F-FDG–PET at
detecting axillary lymph-node metastases ranging from 90% to
100%.
In contrast to the above-mentioned investigations, several
studies have found that 18F-FDG–PET has a low sensitivity at
detecting SLN or axillary lymph node metastases. Indeed, Avril
et al. (14) suggest that 18F-FDG–PET scanning cannot substitute
for histologic analyses of axillary lymph nodes. Their study
compared the diagnostic potential of 18F-FDG–PET with ALND
in 41 breast cancer patients and reported an overall sensitivity
for PET of 79% (19/24). PET sensitivity in the subset of patients
with pT1 tumors was, however, only 33%; four of six patients
had false-negative results, and the largest metastasis undetect-
ed by 18F-FDG–PET measured 12 mm in diameter. Kelemen
et al. (15) also found low PET sensitivity when they compared
18F-FDG–PET scanning with the histolopathologic findings of
SLN biopsies in clinically node-negative T1 and T2 breast can-
cer patients. If the SLN biopsies were negative by hematoxylin
and eosin (H&E) staining, further biopsy sections were obtained
for immunohistochemical (IHC) analyses using polyclonal anti-
cytokeratin (CK) antibodies. Four of five patients with SLN metasta-
ses had false-negative 18F-FDG–PET scans (i.e., 18F-FDG–PET
sensitivity was only 20%), and the missed metastases ranged
from a micro-metastasis (defined as a cohesive cluster of ma-
lignant cells >0.2 mm to 2.0 mm in diameter), which was
identified by IHC only, to macro-metastases up to 11 mm in
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diameter. Furthermore, a Canadian study (24) also found low
PET sensitivity when evaluating the accuracy of 18F-FDG–PET
at detecting axillary lymph node metastases in 41 T1–3 breast
cancer patients. All patients underwent pre-operative 18F-FDG–PET
scan, SLN biopsy, and ALND. The SLN was examined using
serial sectioning and IHC using a monoclonal anti-CK antibody
(CAM 5.2 clone) in addition to standard H&E staining. They
reported that 18F-FDG–PET was unable to identify SLNs that
were found to be node positive by IHC only and that PET had a
sensitivity of 27% at detecting axillary lymph node metastases.
We found similar PET sensitivity results in our own investi-
gation (13), in which we compared pre-operative 18F-FDG–PET
with the histopathologic analysis of SLN biopsies in 31 clini-
cally node-negative pT1 and pT2 breast cancer patients. SLNs
were analyzed by standard H&E staining, IHC (anti-CK anti-
body cocktail CK22 and monoclonal anti-CK antibody Lu-5),
and step sectioning. The step sectioning technique examines
adjacent serial sections of the SLN, which are cut at different
intervals, making them different thicknesses. Each SLN was
analyzed intra-operatively, and lymph nodes that were more than
or equal to 5 mm in diameter were bisected along their longi-
tudinal axis into sections of 3–4 mm and snap frozen. The SLNs
were intra-operatively examined at three levels with H&E
stained sections (cutting interval of 150 m). If no metastases
were diagnosed in the frozen sections, the remaining tissue of
the lymph node was formalin-fixed and embedded in paraffin for
histologic analysis. This residual tissue was then examined using
serial sectioning (cutting interval of 150 m; at least six levels),
and the permanent H&E stained slides were screened for tumor
cells. Of the 14 patients with SLN metastases, eight had false-
negative results by 18F-FDG–PET scan, including three patients
with macro-metastases (4 mm, 4 mm, and 13 mm, respectively),
two patients with micro-metastases (0.8 mm and 1 mm, respec-
tively), and three patients with sub-micro-metastases that re-
mained unidentified. Hence, 18F-FDG–PET had an overall sen-
sitivity of detecting SLN metastases of 43% (6/14).
A study from The Netherlands (16) that evaluated 70 patients
with predominantly early-stage breast cancer who underwent
18F-FDG–PET followed by SLN biopsy and/or ALND has con-
firmed our finding of low PET sensitivity in detecting axillary
lymph node metastases. If the first slice of the SLN was negative
for the presence of metastases, an additional four to six sections
were examined by H&E staining and IHC (using monoclonal
anti-CK antibody CAM5.2). For patients undergoing ALND, up
to two slices per lymph node were examined by IHC. The over-
all sensitivity of 18F-FDG–PET at detecting lymph node metas-
tases was 25% (8/32), and sensitivity was dependent on the
tumor load in the axilla and the 18F-FDG avidity of the primary
tumor. The authors also found that 18F-FDG–PET was unreli-
able in the detection of axillary lymph node micro-metastases,
regardless of the 18F-FDG avidity of the primary tumor.
Our investigation (13) as well as other studies (2,16,25–27)
indicate that the percentage of detected metastases in lymph
nodes increases when using step sectioning and IHC as com-
pared with standard pathology protocols. Most institutions make
only one H&E-stained slice from each node obtained from an
ALND, or they divide the node in half along its longitudinal axis
and make one section from each tissue slice. In addition, serial
or step sectioning of lymph nodes is usually not required as a
standard procedure. In response to the false-negative rates asso-
ciated with the SLN biopsy procedure, new pathology protocols
have emerged, including intra-operative serial frozen sections,
cytokeratin IHC, and molecular biology techniques such as re-
verse transcription polymerase chain reaction. IHC and step sec-
tioning techniques are particularly useful in the detection of
small tumor infiltrates (i.e., micro-metastases), which often re-
main undetected using standard histopathologic analyses. Al-
though large retrospective studies (2) have shown disease-free
and overall survival disadvantages for breast cancer patients
with micro-metastases, therapeutic consequences and the prog-
nostic importance of micro-metastases remain a matter of sci-
entific debate. It should be emphasized, however, that both mi-
cro- and small macro-metastases cannot be identified by PET
scanning, because their diameters (i.e., <3 mm) are below the
current spatial resolution of PET imaging, which is currently
reported to be between 3 mm and 10 mm (28–30). Hence, in-
vestigations comparing pre-operative 18F-FDG–PET with stan-
dard histologic analyses of ALND could miss micro-metastases
and small macro-metastases by both histologic analysis and PET
scanning. Thus, patients with small tumor infiltrates that are
undetectable by PET scan (i.e., false-negatives) might be
wrongly classified as “true-negatives” by histologic analysis,
resulting in incorrectly high sensitivities for PET scanning.
Although step sectioning and IHC would increase the rate of
detection of small tumor infiltrates in axillary lymph nodes, the
systematic use of these techniques is not feasible in the assess-
ment of ALND specimens because these procedures are prohibi-
tively time consuming and costly (2). In contrast, SLN biopsy
offers the advantage that these techniques can be applied on a
small number of lymph nodes. Interestingly, all four reported
studies (13,15,16,24) that compared 18F-FDG–PET with histo-
pathologic analyses of axillary lymph nodes yielded poor sen-
sitivities for PET at detecting metastases (20%–43%, Table 1).
The use of step sectioning and IHC in our investigation (13)
allowed the detection of sub-micro-metastases, all micro-
metastases, and one macro-metastasis, all of which were unde-
tected in the intra-operative frozen section analysis and in the
initial H&E staining. The failure to detect tiny metastatic foci in
large lymph nodes represents a limitation of the frozen section
technique used in standard pathology protocols. Indeed, in our
study (13), the sensitivity of 18F-FDG–PET at detecting sentinel
lymph node metastases, which was initially 88% using standard
H&E staining only, dropped to 43% after step sectioning and
IHC were also used. It should be emphasized that none of the
studies (17–19) that suggest that 18F-FDG–PET is a reliable and
non-invasive alternative to ALND/SLN biopsy used techniques
that would allow the detection of small metastases. Therefore, it
is reasonable to assume that the reported values for sensitivities
of 18F-FDG–PET in those studies—most of them close to
100%—are overly optimistic and do not accurately reflect the
limitations of this diagnostic tool. Therefore, it might be mis-
leading to report the diagnostic potential of 18F-FDG–PET with-
out systematically performing histologic analyses that allow the
detection of small tumor infiltrates.
In contrast to the limited sensitivity of PET scanning in the
detection of small axillary lymph node metastases, most studies
report high specificity (13,16,20–22,24,32) (Table 1). Although
inflammatory processes, such as abscesses and sarcoidosis, can
result in increased 18F-FDG uptake (33,34), the rate of false-
positive results is usually low (0–6%) (13,16,20–22,24,32). Due
to high accuracy, pre-operative PET scanning has been sug-
gested as a tool for tumor staging of patients with suspected
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breast cancer (14,23). Previous studies (14,22) have found that
PET scanning is able to provide additional and useful informa-
tion about the extent of the disease. For example, the identifi-
cation of distant metastases or tumor involvement of level III
axillary lymph nodes, supra-clavicular, or internal mammary
lymph nodes might have important implications in regard to the
choice of local radiotherapy and systemic chemotherapy (14).
However, it is currently premature to recommend a pre-
operative PET scan for all patients with suspicious breast masses
because the diagnostic, quality of life, and economic implica-
tions of this diagnostic tool need further elucidation.
In summary, based on the present literature (14–16) and on
own experience (13), we suggest that PET scanning does not
currently have the adequate spatial resolution to detect both
micro- and small macro-metastatic disease in axillary lymph
nodes of patients with breast cancer. Therefore, PET scanning
cannot serve at this time as a non-invasive alternative to SLN
biopsy. It is possible, however, that with the advent of new
detector materials in clinical practice (e.g., lithium, silicon,
curved crystals), the sensitivity of 18F-FDG–PET will further
improve (35) and could eventually replace invasive procedures
in the evaluation of the nodal status of patients with breast
cancer.
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